Skip to content
Clinical Trials – home

Severe myoclonic epilepsy of infancy Basic Information

3 / 11 trials open to patients15 countries

In short

Severe myoclonic epilepsy of infancy is a rare epileptic syndrome that affects young children, typically appearing in their first year of life with sudden muscle jerks and seizures that can be triggered by fever or heat.

Key points

  • Severe myoclonic epilepsy of infancy typically begins around six months of age with prolonged seizures triggered by fever or heat exposure.
  • Most cases result from spontaneous genetic mutations in the SCN1A gene that occur randomly and are not inherited from parents.
  • The condition causes multiple types of seizures and typically leads to developmental delays and cognitive challenges as children grow.
  • Temperature control is crucial for prevention, as fever and warm environments are major seizure triggers for affected children.
  • Some common anti-seizure medications can actually worsen seizures in this condition, making accurate diagnosis essential.
  • Children typically require lifelong specialized medical care and may need educational support services due to learning difficulties.
  • Any seizure lasting more than five minutes is a medical emergency requiring immediate professional attention.
  • Newer treatments including specific medications like stiripentol and cannabidiol show promise in helping control seizures in this challenging condition.

Understanding Severe Myoclonic Epilepsy of Infancy

Severe myoclonic epilepsy of infancy, also known as Dravet syndrome, is a challenging form of epilepsy that appears during a baby's first year of life. The condition is named after Charlotte Dravet, a French doctor who first described this epileptic syndrome in detail. Unlike milder forms of childhood epilepsy, this condition causes prolonged seizures that can be particularly difficult to control with standard medications.

The condition is characterized by seizures that last longer than typical childhood seizures and often don't respond well to common anti-seizure treatments. These seizures frequently occur when the child has a fever or is exposed to warm temperatures, such as during a hot bath or on a warm day. The name "myoclonic" refers to the rapid, jerking muscle movements that are a key feature of the seizures children experience.

Before approximately six months of age, most children with this condition appear completely healthy and develop normally. However, once seizures begin, parents typically notice a gradual slowing in their child's development. This can be one of the most distressing aspects of the condition for families, as they watch their previously thriving infant begin to struggle with skills that once came easily.

How Common Is This Condition

Severe myoclonic epilepsy of infancy is considered a rare disease. While exact numbers are difficult to determine, it affects a small percentage of children with epilepsy. The condition does not appear to favor one gender over the other significantly, affecting both boys and girls, though some studies suggest a slight variation in incidence between sexes.

The seizures characteristic of this syndrome typically begin around six months of age, though they can start anywhere from the first few months up to about one year. This timing is important for doctors when making a diagnosis, as the age of seizure onset helps distinguish this condition from other types of childhood epilepsy. Most children will have experienced their first seizure by their first birthday.

What Causes Severe Myoclonic Epilepsy of Infancy

The primary cause of severe myoclonic epilepsy of infancy is a genetic mutation. In approximately 70 to 90 percent of cases, the condition results from changes in a gene called SCN1A. This gene provides instructions for making a protein that plays a crucial role in how electrical signals are sent in the brain. When this gene doesn't work properly, the brain's electrical activity becomes unstable, leading to seizures.

What makes this genetic condition particularly challenging is that the mutations are usually not inherited from parents. Instead, they occur spontaneously as new mutations in the affected child. This means that parents typically have no way of knowing their child will develop the condition, and most families have no prior history of this specific syndrome. The mutations appear randomly during the formation of reproductive cells or in early fetal development.

Risk Factors for Developing the Condition

Unlike many other medical conditions, severe myoclonic epilepsy of infancy does not have traditional risk factors that parents can modify or control. The genetic mutations that cause the condition occur randomly and are not linked to anything the mother did or didn't do during pregnancy. Environmental factors, maternal health during pregnancy, or birth complications do not appear to increase the risk of developing this syndrome.

However, once a child has the condition, certain situations can trigger seizures. Fever is one of the most common and significant triggers. Even a slight elevation in body temperature can provoke a seizure in children with this syndrome. Similarly, warm baths, hot weather, or physical exertion that raises body temperature can all lead to seizure episodes. This sensitivity to temperature sets this condition apart from other forms of childhood epilepsy.

In some cases, children may also be sensitive to certain patterns of light or visual stimuli, which can trigger seizures. This is known as photosensitivity and means that flashing lights or certain visual patterns on screens could potentially provoke an episode. Understanding these triggers helps caregivers create a safer environment for affected children.

Recognizing the Symptoms

The first seizures in children with severe myoclonic epilepsy of infancy are typically prolonged convulsions that occur when the child has a fever. These febrile seizures last much longer than the brief seizures some healthy children occasionally experience with high fevers. In children with this syndrome, these initial seizures often last longer than 15 minutes and can affect one side of the body or the entire body.

As the condition progresses, children begin experiencing different types of seizures. Myoclonic seizures cause sudden, brief muscle jerks that look like the child has been startled or has had a sudden spasm. These jerking movements are quick and can affect the arms, legs, or entire body. Children may drop objects they're holding or, if standing, may fall during these episodes.

Beyond the seizures themselves, children with this condition typically experience developmental delays. They may have difficulty learning to speak, walk, or develop motor skills at the expected pace. Many children also display behavioral challenges, including hyperactivity, difficulty focusing, and problems relating to others. In some cases, children may show behaviors similar to those seen in autism. Sleep problems, including difficulty falling asleep or staying asleep, are also common.

The seizures in severe myoclonic epilepsy of infancy tend to worsen as children get older, rather than improving. This progressive nature of the condition means that families must remain vigilant and adapt care strategies as their child grows. The combination of increasing seizure frequency and developmental challenges makes this condition particularly demanding for both children and their caregivers.

How the Disease Affects the Body

In severe myoclonic epilepsy of infancy, the fundamental problem lies in how nerve cells in the brain communicate with each other. The brain relies on carefully controlled electrical signals to function properly. These signals must be precisely timed and regulated to allow normal movement, thinking, and behavior. When the SCN1A gene is mutated, it disrupts the production of proteins called sodium channels that help control these electrical signals.

Sodium channels act like gates in nerve cells, opening and closing to control the flow of sodium ions. This flow of ions is what generates the electrical signals that nerves use to communicate. When these channels don't work correctly, the brain's electrical activity becomes unstable and disorganized. This instability leads to the excessive electrical discharges that cause seizures.

Over time, the repeated seizures and abnormal brain activity can affect brain development and function. This is why children with the condition often experience cognitive impairment, with difficulties in learning, memory, and problem-solving. The brain regions responsible for motor control and coordination are also affected, leading to problems with balance, walking, and fine motor skills. Some children develop ataxia, which means they have trouble coordinating their movements and may appear clumsy or unsteady.

Preventing Seizure Episodes

Since severe myoclonic epilepsy of infancy is caused by genetic mutations that occur spontaneously, there is currently no way to prevent the condition itself from developing. However, once a child is diagnosed, there are important strategies families can use to reduce the frequency and severity of seizures. Understanding and avoiding known triggers is one of the most effective ways to protect children from seizure episodes.

Managing fever is crucial for children with this syndrome. Because elevated body temperature is such a common trigger, parents should act quickly at the first sign of illness. Using fever-reducing medications as soon as a fever begins can help prevent seizure episodes. Keeping the child's environment at a comfortable temperature and avoiding overheating during warm weather or physical activity is equally important.

Maintaining good overall health can also help reduce seizure frequency. Ensuring children get adequate sleep is particularly important, as fatigue and sleep deprivation can lower the threshold for seizures. Establishing consistent bedtime routines and addressing any sleep problems promptly can make a meaningful difference. Similarly, avoiding situations that might trigger seizures, such as exposure to flashing lights in children who are photosensitive, helps create a safer daily environment.

Regular medical follow-up is essential for monitoring the condition and adjusting treatment as needed. Children with severe myoclonic epilepsy of infancy require ongoing care from specialists who understand the unique challenges of this syndrome. Staying current with prescribed medications and reporting any changes in seizure patterns or behavior to healthcare providers helps ensure the best possible management of the condition.

Did you know?

  1. The condition was first comprehensively described by French doctor Charlotte Dravet in 1978, which is why it's often called Dravet syndrome in medical literature.
  2. Even though the condition is genetic, about 70-90% of cases result from brand new mutations that neither parent carries, making it nearly impossible to predict before birth.
  3. Something as simple as a warm bath or playing outside on a hot day can trigger seizures in children with this condition due to their unusual sensitivity to temperature changes.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Severe myoclonic epilepsy of infancy

Recruiting trials first

See all 11 trials →
Quick filters

11 clinical trials in this condition

Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:4-Fluoro-N-[2-[4-(2-Methoxyphenyl)Piperazin-1-Yl]Ethyl]-N-Pyridin-2-Ylbenzamide
  • Sponsor:Hospices Civils De Lyon
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.
Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Ionis Pharmaceuticals Inc.
Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:ZOREVUNERSEN SODIUM
  • Sponsor:Stoke Therapeutics Inc.
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited
See all 11 trials →filters applied: condition = Severe myoclonic epilepsy of infancy

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).